Randomized phase II study of neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed primary glioblastoma multiforme.

被引：0
|
作者：
Hofland, K. F.
Hansen, S.
Sorensen, M.
Schultz, H. P.
Muhic, A.
Engelholm, S.
Ask, A.
Kristiansen, C.
Thomsen, C.
Poulsen, H. Skovgaard
Lassen, U. N.
机构：
[1] Rigshosp, Dept Oncol, Finsenctr 5073, DK-2100 Copenhagen, Denmark
[2] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark
[3] NBG, Onkol Afdeling D, Aarhus, Denmark
[4] Roskilde Hosp, Dept Oncol, Copenhagen, Denmark
[5] Dept Oncol Malmoe Lund, Lund, Sweden
[6] Rigshosp, Ctr Diagnost, Dept Radiol, DK-2100 Copenhagen, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.2052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2052
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Response to correspondence on an exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
    Tanaka, Toshihide
    Takei, Jun
    Sasaki, Hikaru
    JOURNAL OF NEURO-ONCOLOGY, 2024, 170 (02) : 465 - 466
  • [22] Bevacizumab in Combination With Radiotherapy and Temozolomide for PatientsWith Newly Diagnosed Glioblastoma Multiforme
    van Linde, Myra E.
    Verhoeff, Joost J. C.
    Richel, Dirk J.
    van Furth, Bwouter R.
    Reijneveld, Jaap C.
    Verheul, Henk M. W.
    Stalpers, Lukas J. A.
    ONCOLOGIST, 2015, 20 (02): : 107 - 108
  • [23] Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
    Kortmann, Rolf-Dieter
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (10) : 670 - 671
  • [24] Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma
    Omuro, Antonio
    Beal, Kathryn
    Gutin, Philip
    Karimi, Sasan
    Correa, Denise D.
    Kaley, Thomas J.
    DeAngelis, Lisa M.
    Chan, Timothy A.
    Gavrilovic, Igor T.
    Nolan, Craig
    Hormigo, Adilia
    Lassman, Andrew B.
    Mellinghoff, Ingo
    Grommes, Christian
    Reiner, Anne S.
    Panageas, Katherine S.
    Baser, Raymond E.
    Tabar, Viviane
    Pentsova, Elena
    Sanchez, Juan
    Barradas-Panchal, Renata
    Zhang, Jianan
    Faivre, Geraldine
    Brennan, Cameron W.
    Abrey, Lauren E.
    Huse, Jason T.
    CLINICAL CANCER RESEARCH, 2014, 20 (19) : 5023 - 5031
  • [25] Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
    Lai, Albert
    Tran, Anh
    Nghiemphu, Phioanh L.
    Pope, Whitney B.
    Solis, Orestes E.
    Selch, Michael
    Filka, Emese
    Yong, William H.
    Mischel, Paul S.
    Liau, Linda M.
    Phuphanich, Surasak
    Black, Keith
    Peak, Scott
    Green, Richard M.
    Spier, Cynthia E.
    Kolevska, Tatjana
    Polikoff, Jonathan
    Fehrenbacher, Louis
    Elashoff, Robert
    Cloughesy, Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 142 - 148
  • [26] Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM)
    Vredenburgh, J. J.
    Desjardins, A.
    Reardon, D. A.
    Peters, K.
    Kirkpatrick, J.
    Herndon, J. E.
    Marcello, J.
    Bailey, L.
    Threatt, S.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
    O. L. Chinot
    T. de La Motte Rouge
    N. Moore
    A. Zeaiter
    A. Das
    H. Phillips
    Z. Modrusan
    T. Cloughesy
    Advances in Therapy, 2011, 28 : 334 - 340
  • [28] AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
    Chinot, O. L.
    Rouge, T. de la Motte
    Moore, N.
    Zeaiter, A.
    Das, A.
    Phillips, H.
    Modrusan, Z.
    Cloughesy, T.
    ADVANCES IN THERAPY, 2011, 28 (04) : 334 - 340
  • [29] PHASE II STUDY OF BEVACIZUMAB, TEMOZOLOMIDE, AND HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY (HFSRT) FOR NEWLY DIAGNOSED GLIOBLASTOMA
    Omuro, Antonio
    Beal, Kathryn
    Correa, Denise
    Chan, Timothy
    DeAngelis, Lisa
    Gavrilovic, Igor
    Nolan, Craig
    Hormigo, Adilia
    Lassman, Andrew B.
    Kaley, Thomas
    Mellinghoff, Ingo
    Grommes, Christian
    Panageas, Kathryn
    Reiner, Ann
    Barradas, Renata
    Abrey, Lauren
    Gutin, Philip
    NEURO-ONCOLOGY, 2011, 13 : 59 - 60
  • [30] Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
    Carmen Balana
    Ramon De Las Penas
    Juan Manuel Sepúlveda
    Miguel J. Gil-Gil
    Raquel Luque
    Oscar Gallego
    Cristina Carrato
    Carolina Sanz
    Gaspar Reynes
    Ana Herrero
    Jose Luis Ramirez
    Pedro Pérez-Segura
    Alfonso Berrocal
    Jose Maria Vieitez
    Almudena Garcia
    Sergio Vazquez-Estevez
    Sergi Peralta
    Isaura Fernandez
    Ivan Henriquez
    Maria Martinez-Garcia
    Juan Jose De la Cruz
    Jaume Capellades
    Pilar Giner
    Salvador Villà
    Journal of Neuro-Oncology, 2016, 127 : 569 - 579
12345